Toronto Dominion Bank
SABSW icon

Toronto Dominion Bank’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Toronto Dominion Bank’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Buy
+300
New +$6 ﹤0.01% 2271
2025
Q4 		– Sell
-200
Closed -$5 – 2251
2025
Q3 		$5 Buy
+200
New +$7 ﹤0.01% 1905

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Toronto Dominion Bank's SABSW Position: Q2 2026 in Review

Toronto Dominion Bank opened a new position in SAB Biotherapeutics Warrant (SABSW) in Q2 2026: 300 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #2271 among its holdings. This is a return to the name: Toronto Dominion Bank previously reported a position in SABSW as recently as Q3 2025.

Toronto Dominion Bank first reported a position in SABSW in Q3 2025 and has held it in 2 quarters since. The position peaked at $5 in Q3 2025. 8 funds tracked by Wall St. Rank hold SABSW as of Q2 2026.

  • Toronto Dominion Bank held 300 shares of SAB Biotherapeutics Warrant worth $4 as of Q2 2026.
  • SAB Biotherapeutics Warrant was a new Toronto Dominion Bank position in Q2 2026.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q2 2026, its #2271 holding.
  • Toronto Dominion Bank first reported a position in SAB Biotherapeutics Warrant in Q3 2025 and has held it in 2 quarters since.
  • Toronto Dominion Bank's SAB Biotherapeutics Warrant position peaked at $5 in Q3 2025.
  • 8 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2026.

Based on Toronto Dominion Bank's 13F filing for Q2 2026, filed 14 Aug 2026.